If you’ve been following the BPA conversation over the past decade, you probably have a vague sense that the science kept shifting, regulators kept disagreeing, and at some point, you stopped being sure whether your reusable water bottle was safe.
We’re seeing more sensationalized headlines and conversation about BPA. Let’s take a look at what the current evidence says.
Top Takeaways
- BPA is a widely used chemical in plastics and food packaging that has been studied for decades.
- The CLARITY-BPA study is the most comprehensive research effort to date and helps bridge gaps between academic and regulatory science.
- Large regulatory studies have not found consistent evidence of harm at typical human exposure levels.
- Some academic studies raise questions about low-dose effects, but results are inconsistent and often not reproducible.
What is BPA, and where do we find it?
Bisphenol A (BPA) is a chemical ingredient that’s been used since the 1960s to make polycarbonate plastics and epoxy resins. It is used in a wide range of everyday products like the lining inside metal food cans, reusable plastic containers, bottle caps, water pipes, and even thermal paper receipts.
Because of that widespread use, exposure is widespread as well. Biomonitoring studies in the United States have consistently shown that most people have detectable levels of BPA in their bodies. That’s not inherently alarming because we know that detection doesn’t mean harm. It reflects how widely the material is used.
Why are people worried about BPA exposure?
Due to the widespread use of BPA in plastics, researchers investigated the ingredient to determine whether it harms our health. Some researchers are concerned that, at low doses, BPA can mimic estrogen to an extent that it could interfere with normal hormone signaling.
It’s important to remember that hazard and risk are not the same thing. The fact that a substance can interact with biological systems does not automatically mean it does cause harm at real-world exposure levels.
What was done to investigate BPA safety exposure?
To address years of conflicting research, the National Toxicology Program (NTP), the U.S. Food and Drug Administration (FDA), and the National Institute of Environmental Health Sciences (NIEHS) launched the CLARITY-BPA program.
The CLARITY-BPA program developed one of the largest and most expensive studies ever conducted on a single chemical ingredient, costing roughly $30 million. The program lasted 5 years and was intentionally designed to resolve long-standing disagreements in BPA research.
It combined a large, guideline-compliant regulatory study (the kind typically used for safety decisions) with a series of independent academic laboratory studies exploring specialized endpoints. Uniquely, both sets of researchers worked from the same pool of animals, under the same exposure conditions, and with blinded samples to reduce bias.
Blinded samples were critically important because they ensured that researchers were unaware which animals were exposed to high, low, or no BPA. This means it eliminated many common biases, resulting in a much stronger outcome.
By using shared, blinded samples and identical exposures, the goal was to determine whether differences in findings were due to study design or true biological effects. Ultimately, it aimed to improve how we evaluate chemical safety.
What did the CLARITY BPA study find?
Regulatory science tends to prioritize findings that are robust, reproducible, and clearly linked to adverse outcomes. Academic research often explores earlier, subtler biological changes that do not necessarily translate into real-world risk.
The core regulatory study, conducted under standardized conditions, found minimal evidence of adverse effects at doses relevant to human exposure. This is the foundation for the FDA’s current position that BPA is safe at typical exposure levels.
Some academic researchers reported biological changes across endpoints such as immune function, development, metabolism, and neurobehavior. A subset of these findings occurred at lower doses, but they were not consistent across studies, not always dose-dependent, and not clearly linked to adverse health outcomes.
While BPA can interact with the estrogen receptor, it does so very weakly. The body’s natural hormone, estradiol, binds to this receptor 1,000 to 10,000 times more strongly than BPA. In other words, BPA’s ability to activate the estrogen receptor is significantly lower compared to the body’s own hormone.
Ultimately, the study showed that disagreement around BPA is not about whether effects exist, but rather defining if effects equate to harm.
What happens when we remove BPA?
Ingredients found in foods and products serve a purpose. BPA is no different. Manufacturers cannot remove BPA without replacing it with another ingredient that serves the same or a similar purpose, so it’s replaced with structurally and functionally similar ingredients, such as Bisphenol S (BPS) and Bisphenol F (BPF).
The difference between ingredients like BPA, BPS, and BPF lies in the level of study on those specific ingredients. Ingredients like BPS and BPF have not had $30M safety studies that generated robust data profiles.
Manufacturers who have chosen to replace BPA frequently do so with ingredients we know significantly less about and will likely never know as much about, due to the expense and time required to conduct a large-scale safety study.
What else do I need to know about BPA exposure?
For most people, BPA exposure comes from food-contact materials, such as the epoxy linings of metal cans. That means exposure isn’t constant. Exposure tends to happen in spikes, tied to meals or specific products, rather than as a steady, continuous dose.
Unlike some chemical ingredients that persist and accumulate in the body, BPA is rapidly metabolized and eliminated, with a biological half-life of hours. That means BPA levels reflect recent exposure rather than long-term accumulation.
While avoiding exposure to those ingredients may not be completely possible, especially in medical settings where BPA ingredients are needed to ensure specific medical equipment works effectively, you can reduce your exposure by choosing non-plastic-containing options.
The good news.
BPA is one of the most extensively studied chemicals in the food and consumer product space, and that matters. It means we’re not making decisions in the dark because we have decades of data across animal studies, human biomonitoring, and large-scale efforts like CLARITY to inform how we evaluate safety.
Just as importantly, BPA does not persist in the body. It is rapidly metabolized and eliminated, so exposure reflects recent contact rather than long-term accumulation.
And finally, the ongoing debate itself is a sign that the system is working. Scientists are continuing to test assumptions, refine methods, and re-evaluate evidence as new data emerge. This is how science is supposed to work.
If you have any questions about ingredients or ideas for a blog post, please send us an email or submit your idea to us at go.msu.edu/cris-idea.
Citations and Further Reading
CLARITY-BPA Research Program. (2021). NTP research report on the consortium linking academic and regulatory insights on bisphenol A toxicity (CLARITY-BPA): A compendium of published findings. National Toxicology Program.
National Toxicology Program. (2018). NTP Research Report on the CLARITY-BPA Core Study: A Perinatal and Chronic Extended-Dose-Range Study of Bisphenol A in Rats (NTP RR 9).
National Toxicology Program. (2025). CLARITY-BPA Program. https://ntp.niehs.nih.gov/research/topics/bpa
National Toxicology Program. (2026). CLARITY-BPA data repository. https://cebs.niehs.nih.gov/cebs/program/CLARITY-BPA